Innovacell
Innovacell Biotechnologie AG is an innovative biotechnology company that develops personalized cell therapies for treatment of incontinence.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
$20.0m | Series C | ||
| Total Funding | 000k | ||
Related Content
Innovacell is a biotechnology company focused on improving health through advanced regenerative cell therapies. The company specializes in treating incontinence and urination disorders by using patients' own cells to cure diseases fundamentally. Innovacell serves patients suffering from these conditions, primarily in the Japanese market, where it has established a significant presence since 2021. The business model revolves around research, development, and manufacturing of regenerative products, leveraging patented technology for the separation, cultivation, and use of bone muscle cells. Revenue is generated through the sale of these innovative therapies, supported by both public and private investment. Innovacell's mission is to enhance the quality of life (QOL) for its patients by providing effective, long-term solutions to chronic health issues.
Keywords: regenerative therapy, incontinence, urination disorders, cell therapy, biotechnology, health improvement, quality of life, Japanese market, patented technology, bone muscle cells.